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ABSTRACT 
Systemic Sclerosis (SSc) is an autoimmune rheumatic disease, characterized by 
fibrosis of the skin and internal organs, vasculopathy and the production of 
autoantibodies. Cardiac and pulmonary disease manifestations are major causes 
of morbidity and mortality. Microvascular manifestations such as digital ulcers 
and Raynaud´s phenomenon are common, but whether macrovascular disease is 
also enhanced in SSc has not been clear. In a cross-sectional design we examined 
the heart, the macro- and microvasculature and how vascular disease 
manifestations correlated to each other, to SSc subsets and to biomarkers. 
Population based age- and gender-matched controls were used as comparators.  
Carotid atherosclerosis, measured by ultrasound, and history of ischemic arterial 
events (IAE) were investigated in 111 SSc patients and 105 controls. Previous 
IAE were three times more common in the patients, especially ischemic heart 
disease (IHD) and ischemic peripheral vascular disease (IPVD). Measures of 
atherosclerosis, i.e. intima media thickness, plaque occurrence and ankle-
brachial index, did not differ on a group level, but patients with anticentromere 
antibodies  (ACA+) had more IAE and more plaques than ACA- patients and 
controls. Echocardiographic (echo) findings and their association with cardiac 
troponin I (cTnI), N-terminal pro brain natriuretic hormone (NT-proBNP) and 
Uric Acid (UA) were investigated. The patients had higher levels than controls 
of cTnI and NT-proBNP but not of UA. All three biomarkers were associated 
with echo abnormalities among the SSc patients. A low left ventricular ejection 
fraction (LVEF) and hypokinesia were more common in patients but associated 
with previous IHD. Patients had more valve regurgitations than controls and 15 
patients, but no controls, had an elevated echo-estimated systolic pulmonary 
arterial pressure (ePAP). A standard 12-lead electrocardiogram (ECG) was 
performed on all, and Holter-ECG on a subgroup of participants. Conduction 
defects, especially left bundle branch block (LBBB) and ventricular extrasystoles 
were more common in the patient group. Finally, the nailfolds of 163 SSc 
patients were examined by widefield microscopy for signs of dilated capillaries, 
avascular areas and capillary density. SSc patients with a higher ePAP, ACA+, 
digital ulcers and IAE, especially IPVD, had a lower nailfold capillary density 
These studies demonstrate that patients with SSc had more IAE than controls, 
and SSc patients with previous IAE also have a disturbed microcirculation in the 
nailfolds. It is a new observation that both macrovascular IAEs and accelerated 
atherosclerosis prevails in the ACA+ SSc subgroup. SSc patients had more valve 
regurgitations, higher ePAP and more left and right ventricular impairment on 
echo. These echo abnormalities were associated with higher levels of the cardiac 
biomarkers, NT-proBNP and cTnI. The latter is a new clinically useful finding. 
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1 SYSTEMIC SCLEROSIS 
 
1.1 INTRODUCTION:  
Systemic sclerosis (SSc) is a relatively rare rheumatic disease affecting a 
diversity of organs (1). The first known patient case was described in 1753 when 
the Italian doctor Carlo Curtzio described a young female with hard, wooden like 
and cold skin, despite good pulses. The term scleroderma was introduced around 
1850, but it was not until the beginning of the 1900th century that it became clear 
that many other organs than the skin are affected in this disease. Maurice 
Raynaud, who gave the cold induced colour-changing of the fingers the eponym 
“Raynaud´s phenomenon”, was the first to realize that there was an association 
between the cold, colour changing of the fingers and systemic sclerosis (2).  
The combination of five different disease characteristics, namely calcinosis, 
Raynaud´s phenomenon, esophagus involvement, sclerodactyly and 
telangiectasia was introduced in 1964 as the CREST-syndrome, a sub type of 
scleroderma (3) to be distinguished from the more severe “progressive systemic 
sclerosis”. Although many have suggested abandoning these names because of 
imprecise and overlapping features (4, 5) the International Statistical 
Classification of Diseases and Health Problems, 10th Revision (ICD-10) still 
distinguishes between the terms CREST (M 34.1) and progressive systemic 
sclerosis (M34.0) (6) 
 
 
1.2 CLASSIFICATION CRITERIA: 
In 1980 the American Rheumatism Association (ARA, today called American 
College of Rheumatology; ACR) published preliminary classification criteria for 
SSc (7). Although preliminary, these criteria have been used in almost every 
clinical study since then. Their purpose is to correctly select patients with 
established SSc for scientific studies and to distinguish the entity from other 
more localized scleroderma-like disorders: 
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Table 1. The 1980 ARA major and minor criteria for the diagnosis of SSc. 
Major criterion: Proximal scleroderma: Typical sclerodermatous skin changes: 
tightness, thickening, and non-pitting induration, excluding the 
localized forms of scleroderma, proximal to metacarpophalangeal or 
metatarsophalangeal joints; affecting other parts of the extremities, 
face, neck, or trunk (thorax or abdomen); usually bilateral, 
symmetrical, and almost always including sclerodactyly 
Minor criteria: 1. Sclerodactyly: above-indicated changes limited to fingers and toes 
 2. Digital pitting scars or loss of substance from the finger pad: 
depressed areas at tips of digits or loss of digital pad tissue as a result 
of digital ischemia rather than trauma or exogenous causes 
 3. Bibasilar pulmonary fibrosis: bilateral reticular pattern of linear or 
lineo-nodular densities which are most pronounced in basilar portions 
of the lungs on standard chest roentgenogram; may assume appearance 
of diffuse mottling or “honeycomb lung”, and should not be 
attributable to primary lung disease.  
Patients with the major criterion or 2 minor criteria are classified as having Systemic sclerosis 
A further subgrouping of the patients was suggested in 1988 by LeRoy et al, 
dividing the patients, depending on how widespread the skin involvement is, into 
diffuse cutaneous SSc (dcSSc-skin sclerosis on trunk, thighs, upper arms, 
abdomen), limited cutaneous SSc (lcSSc- skin sclerosis confined to arms and 
legs below elbows and knees and/or skin sclerosis of the face) and limited 
Systemic sclerosis (lSSc- a patient group which lacks the characteristic fibrotic 
skin, but otherwise has the characteristics of SSc) (4).  
The preliminary 1980 ARA criteria have a good specificity for recognising 
established SSc patients. But, the last 20 years many efforts have been made to 
identify the patients earlier, before irreversible organ damages occurs. Many 
studies have demonstrated that antinuclear antibodies (ANA), in particular some 
sub-specificities (anticentromere, anti–topoisomerase I/anti–Scl-70, anti–RNA 
polymerase III), and deranged nail fold capillary loops had a high predictive 
value for the development of SSc in the future (8-10) These observations have 
lead to the development of the new ACR/EULAR 2013 classification criteria for 
Systemic sclerosis (11). 
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Table 2. The American College of Rheumatology/European League Against 
Rheumatism criteria for the classification of systemic sclerosis (SSc)* 
Item Sub-item(s) Weight/score† 
Skin thickening of the fingers of 
both hands extending proximal to 
the metacarpophalangeal joints 
(sufficient criterion) 
- 9 
Skin thickening of the fingers (only 
count the higher score) 
Puffy fingers 
Sclerodactyly of the fingers (distal to the 
MCP joints but proximal to the PIP 
joints) 
2 
4 
Fingertip lesions 
(only count the higher score) 
Digital tip ulcers  
Fingertip pitting scars  
2 
3 
Telangiectasia - 2 
Abnormal nailfold capillaries - 2 
Pulmonary arterial hypertension 
and/or interstitial lung disease 
(maximum score is 2) 
Pulmonary arterial hypertension  
Interstitial lung disease 
2 
2 
Raynaud’s phenomenon - 3 
SSc-related autoantibodies 
(anticentromere, anti–
topoisomerase I/anti–Scl-70, anti–
RNA polymerase III) (maximum 
score is 3) 
Anticentromere antibodies (ACA) 
Anti-topoisomerase I (ATA) 
Anti–RNA polymerase III (ARA) 
3 
3 
3 
* These criteria are applicable to any patient considered for inclusion in an SSc study. The criteria are not applicable to 
patients with skin thickening sparing the fingers or to patients who have a scleroderma-like disorder that better explains 
their manifestations (e.g., nephrogenic sclerosing fibrosis, generalized morphea, eosinophilic fasciitis, scleredema 
diabeticorum, scleromyxedema, erythromyalgia, porphyria, lichen sclerosis, graft-versus-host disease, diabetic 
cheiroarthropathy).† The total score is determined by adding the maximum weight (score) in each category. Patients 
with a total score of ≥ 9 are classified as having definite SSc. 
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1.3 EPIDEMIOLOGY  
The incidence and prevalence of systemic sclerosis is hard to examine, especially 
because of the long delay between the onset of the first symptom to diagnosis, 
the overlap between SSc and other rheumatic disease and “the scleroderma 
mimics”. Two recent reviews of epidemiological studies show a large difference 
between countries, with prevalence in general between 50-300/ million 
inhabitants and incidence 4-22/million inhabitants. The highest incidence and 
prevalence in the USA and Australia, and the lowest in northern Europe and Asia 
(12, 13). Some have also described a latitude dependent distribution of the 
disease with a higher prevalence in the south regions, especially in Europe (13). 
A new study from Sweden opposed this theory by finding a relatively high 
prevalence of SSc patients, especially when using the new classification criteria 
(14). The observations that SSc is clustered in some areas have given rise to the 
suspicion that environmental exposures such as silica dust or organic solvents 
are important for the pathogenesis of SSc (15).  The disease affects more females 
than males, with ratios varying between 5-8:1.  
Figure 1: Prevalence and incidence of 
Systemic sclerosis in Europe. 
 
 
 
References: (14, 16-23) 
Country  prevalence* incidence* 
Iceland         71             3.8 
Norway       72 (99)        6-11 
Finland           -              3.7 
Sweden       235 (305)    14 (19) 
England        88               - 
France           132 
Spain             277             14 (23) 
Italy              254              32 
Greece           154             11 
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1.4 PATHOGENESIS  
There are three main features involved in the pathogenesis of systemic sclerosis:  
 
 
 
 
 
 
1.4.1 Fibrosis  
The connective tissue offers a structural network to support organ function. The 
most common cell found in the connective tissue is the fibroblast, the major 
contributor to connective tissue homeostasis. The fibroblasts are highly active 
cells that regulate extracellular matrix (ECM) turnover though the production of 
both matrix metalloproteinases (MMPs), which degrades EMC, and tissue 
inhibitors of metalloproteinases (TIMPs), which inhibits the MMPs (24).  
Serum levels and skin biopsy expression of TIMPs are higher in SSc-patients as 
compared with controls, suggesting an imbalance in ECM turnover (25, 26).  
When a tissue is damaged, fibroblast can transform into myofibroblasts. These 
cells have a structure “somewhere between a fibroblast and a smooth muscle 
cell” and they are identified by their profound endoplasmatic reticula in 
combination with contractile stress filaments expressing alpha-smooth muscle 
actin. The origin of the myofibroblasts is not only the fibroblast; they can also 
develop from epithelial-, endothelial- or smooth muscle-cells. Myofibroblasts 
produce many ECM proteins, the most abundant are collagen type I and type III. 
They are important for repair of damaged tissues. When the repair process is 
completed the myofibroblasts disappear from the wound sites through apoptosis, 
deactivated or cleared by other cells. They leave a hypocellular scar tissue (27).  
In fibrotic tissue, such as the SSc skin or the lung in SSc, the myofibroblast 
persist, which seems to depend on defective apoptosis and an enhanced 
sensibility to growth factors and pro-fibrotic stimuli (28). The SSc-fibroblasts 
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seem to produce excess ECM proteins, such as collagen, even in the absence of 
extrinsic stimuli, suggesting an autocrine activation (29). 
The first event, initiating the transformation of fibroblasts to myofibroblasts in 
SSc, is likely activation of endothelial cells and platelets caused by infection, 
ischemia-reperfusion, toxins or autoantibodies resulting in tissue infiltration of 
inflammatory cells and secretion of different cytokines and growth factors. 
Transforming growth factor-β (TGF-β) has been considered the main regulator 
of fibrogenesis. It is mainly produced by macrophages but also by other cells, 
including endothelial cells. Both in vivo and in vitro studies have highlighted the 
importance of TGF-β in SSc (30). 
There are also other cytokines, which play a crucial roll in fibrogenesis such as 
connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF), 
interleukin (IL)-1β, IL-4, IL-6, IL-13, IL-17A, and type I interferon (IFN) (31).  
 
1.4.2 Vasculopathy 
Vascular abnormalities are a major component of SSc, but little is known about 
the events or mechanisms that initiate the vascular injury. The earliest clinical 
symptom of SSc, Raynaud´s phenomenon, relates to disturbances in the 
peripheral vascular system that may precede other manifestations by years. The 
initial events leading to vascular alterations are thought to, in similarity to the 
initial phase of fibrosis, involve damage to the endothelial cells (EC) caused by 
infection, immune mediated cytotoxicity, ischemia-reperfusion injury or anti-
endothelial antibodies (32). 
EC adhesion ligands are up regulated in response to damage. They promote the 
binding, rolling and migration of inflammatory cells into the interstitial space 
from where they can infiltrate the tissue. Simultaneously, vascular smooth 
muscle cells proliferate in response to growth factors resulting in intimal 
proliferation and matrix deposition in the vessel wall. These processes can 
eventually lead to complete occlusion of the vascular lumen (33). 
The loss of viable ECs also leads to an imbalance in vasoactive factors such as 
overproduction of the vasoconstrictor endothelin-1 (ET-1) and underproduction 
of the vasodilators nitric oxide (NO) and prostacyclin. The enhanced apoptosis 
of EC results in a loss of capillaries, which is easily detectable with nailfold 
capillaroscopy. These changes are considered to constitute the first steps in the 
pathogenesis of SSc (32). 
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In healthy subjects the loss of EC and tissue ischemia induce enhanced 
production of angiogenic growth factors, especially vascular endothelial growth 
factor (VEGF), which initiates vasodilatation, proliferation and migration of ECs 
to form new vessels, i.e. angiogenic sprouting (33).  
VEGF levels are increased in both the plasma and the skin of SSc patients, but 
despite this, angiogenesis is insufficient (34-36). The underlying mechanisms are 
not fully understood. They seem to involve harmful effects of prolonged 
exposure to high levels of VEGF (35, 37) and overexpression of a more anti-
angiogenetic splice-variant of VEGF (38)  
Not only angiogenesis (the building of new vessels from existing vessels) but 
also vasculogenesis (the building of new vessels from progenitor cells) are 
impaired in SSc. Patients with digital vascular lesions and high “SSc severity 
scores” had lower endothelial progenitor cell (EPC) counts in the circulation, 
suggesting that inadequate recruitment of bone marrow derived circulating EPCs 
may be related to the reduced vascular repair capacity in SSc. Reduced number 
of EPCs has also been associated with capillary loss and severe internal organ 
involvement (predominantly cardiac) as well as with the development of PAH 
(39-41).  
The release of von Willebrand factor (vWF) into the circulation reflects the 
activity of the vascular disease in SSc (42). vWF is mainly released from the 
endothelium. In the skin, it is also found in the perivascular and interstitial 
matrix, which suggests that the local microvessels of the papillary layer of the 
skin are damaged in SSc. When the high molecular-weight vWF binds to sub 
endothelial collagen fibres it can form bridges between the sub endothelial 
matrix and platelet receptors, and thus contribute to platelet adhesion and 
aggregation, and later to the formation of thrombosis. Through these 
mechanisms, local vascular damage and the subsequent release of vWF may 
contribute to local pathogenic processes (43). 
Platelets are the major storage and delivery vehicles for both pro- and anti- 
angiogenic growth factors, including VEGF (33).  
ET-1 is predominantly synthesized by ECs and smooth muscle cells. It can 
regulate the growth of mesenchymal cells and induce collagen and fibronectin 
production and cell migration. ET-1 is thus one of the main regulators of ECM 
synthesis and vascular and interstitial remodelling. In SSc, increased plasma ET-
1 levels are involved in enhanced vasoconstriction, vascular EC proliferation, 
smooth muscle hypertrophy and irreversible vascular remodelling (32). 
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1.4.3 Activation of immune system:  
Inflammation: There are several studies examining the different inflammatory 
cytokines in SSc, often with divergent results. As Th1 lymphocytes mainly 
produce cytokines that are involved in cellular immune response, such as IFN-γ, 
TNF-α and IL-2 these are often referred to as “proinflammatory” in SSc. These 
cytokines of mainly Th1 origin are often elevated in the early stages of SSc. Th2 
lymphocytes mainly produce IL-4, IL-13, IL-5, IL-6 and IL-10 and are believed 
to be more “profibrotic” in SSc. IL-6, IL-4 and IL-13 are able to stimulate the 
production of collagen, and they can inhibit collagenase synthesis, which favours 
fibrosis. IL-4 and IL-13 both stimulate B cell differentiation, with consequent 
production of autoantibodies and isotype switching. Additionally, IL-13 induces 
TGF-β gene expression (44). 
There is evidence of elevated IL-6 levels in the circulation and the skin in 
patients with SSc. IL-6 has a pro-inflammatory function in the presence of TGF-
β/ IL-21 via induction of IL-17 differentiation. IL-6 also inhibits the 
differentiation of T regulatory lymphocytes and stimulates the production of 
collagen (45).  
Additionally it has been demonstrated that more traditional measures of 
inflammation are important in SSc. Thus an erythrocyte sedimentation rate 
(ESR) > 25 mm is a predictor of mortality and an elevated CRP, especially 
prevalent in early dcSSc, is associated with SSc disease activity, severity, and 
poorer survival (46).  
 
Antibodies: Antinuclear antibodies (ANA) are frequent in SSc, present in >90% 
of the patients. The most common antibodies in SSc patients are anticentromere 
antibodies (ACA), antitopoisomerase I antibodies (ATA)/Scleroderma-70 
antibodies (Scl-70) and anti RNA polymerase III antibodies (ARA). Presence of 
one of these antibodies constitutes one of the classification criteria in the new 
ACR/EULAR classification of SSc (11) The presence of these antibodies has 
been shown to predict the onset of SSc before a clinical diagnosis is established 
(47, 48).  
About 20-40% of the SSc patients have ACA, but the frequency is depending on 
ethnicity, with a lower frequency in Afro-Americans and Thai SSc patients. The 
sensitivity of ACA is in the range of 20-40% and the specificity >90% (49).  
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ACA have been associated with lcSSc (50, 51), pulmonary arterial hypertension 
(52, 53) but they seems to have a lower frequency among patients with severe 
pulmonary fibrosis and renal crisis (54). ACA have also been associated with a 
more favourable prognosis than other antibodies. 
ATA are found in 10-40% of the SSc patients and the specificity can be as high 
as 99% but the sensitivity is less than 25%. ATA have been associated with a 
poorer prognosis, pulmonary fibrosis, musculoskeletal, and cardiac involvement 
(48, 50, 52). 
ARA occurs in 10-20% of the SSc-patients and they are associated with dcSSc 
and a higher risk of scleroderma renal crisis (55, 56). 
Sjögren´s Syndrome antibodies A and B (SSA/SSB) are found in about 20% of 
the SSc patient (49). 
 
 
1.5 CLINICAL FEATURES  
There are many different clinical manifestations in systemic sclerosis. The most 
common are thickness of the skin, Raynaud´s phenomenon and gastrointestinal 
symptoms, such as reflux, bloating and diarrhoea. Arthritis, myositis and/or 
calcinosis (calcium deposit under the skin) are seen in some patients (57). 
About 50% of the patients experience at least one digital ulcer during the disease 
course. It is not uncommon that ulcers recur and they can lead to digital loss. 
The high mortality rate, pooled standardized mortality ratio (SMR) 3.5, observed 
in SSc is mainly associated with cardiac or pulmonary disease manifestations 
(58).  Pulmonary fibrosis is prevalent in 40-80% of SSc patients depending of 
diagnosis modality or subgroup. Most cases have a benign course, but about 
15% have more widespread pulmonary fibrosis (57). 
Several disease manifestations, such as severe pulmonary fibrosis, left sided 
heart failure, pulmonary embolism and pulmonary arterial hypertension (PAH) 
can lead to pulmonary hypertension (PH) in SSc. Between 7-15 % have PAH, a 
severe life-threatening condition, which arises as a consequence of vascular 
disease in the lungs (57). 
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1.6 TREATMENT  
There are no curative treatments for SSc. Most of the patients have histamine2-
receptor antagonists (H2 blockers) the gastrointestinal problems and calcium 
channel-blockers for Raynaud´s Phenomenon (59) 
Corticosteroids are used in low dosages for shorter periods in some patients, 
especially in SSc patients with myositis or arthritis. Higher corticosteroid 
dosages have been associated with the development of SCR and should therefor 
be avoided (60) 
Disease modifying anti rheumatic drugs (DMARD) such as methotrexate are 
used for in widespread active skin disease and cyclophosphamide and 
mycophenolate mofetil for alveolitis/pulmonary fibrosis. Endothelin-antagonists, 
phosphodiesteras-blockers and prostacyclin are used for severe vascular disease 
such as PAH and also for recurrent digital ulcers (59). 
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2 CARDIOVASCULAR DISEASE AND 
ATHEROSCLEROSIS 
 
2.1 ATHEROSCLEROSIS 
CVD is the leading cause of mortality in the world and in Sweden about 40% of 
all deaths are due to CVD (61). Atherosclerosis is considered to be the main 
cause of CVD. The process of atherosclerosis begins already in childhood with 
the development of ”fatty streaks” in the intima of the vessels. These streaks 
gradually transform into fibromuscular plaques (62).  
The cores of the plaques are filled with lipids and necrotic debris. The plaques 
are surrounded with a fibromuscular cap, formed by the smooth muscle cells of 
the media. The plaques grow slowly. Initially they expand outwards with 
preserved vascular lumen, but with time they can cause narrowing of the lumen, 
obstruct the blood flow and thus trigger symptoms of ischemia (63). The fibrous 
cap can also eventually become thin and unstable, resulting in a vulnerable 
plaque with a high risk of rupture. If rupture occurs, the necrotic debris of the 
core is exposed to the circulating blood and a thrombus is formed, which can 
lead to total occlusion of the vessel (64).  
Myocardial infarction, ischemic stroke, sudden cardiac death, chronic ischemic 
heart disease and peripheral arterial disease are the most common clinical 
manifestations of atherosclerosis.  
The atherosclerotic process is a common feature in most individuals, but the 
progression to vulnerable plaques, or plaques, which obstruct the vessel lumen, 
are dependent on several factors. During the last 20 years, atherosclerosis has 
been recognized as a chronic inflammatory disease, where local and systemic 
inflammation is thought to play an important role (65). The origin of 
atherosclerosis is believed to take place in the endothelium. Endothelial 
activation or injury can have varying causes. An activated endothelium is prone 
to take up oxidized LDL (oxLDL) to be engulfed by subendothelial macrophages 
that transform into foam cells. Foam cells make up the core of the atheroma, 
which with time can develop into a culprit lesion (66-68). 
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Figure 1. Atherosclerotic plaque stable, and vulnerable 
  
2.2 METHODS TO MEASURE ATHEROSCLEROSIS AND 
ENDOTHELIAL DYSFUNCTION: 
One of the most commonly used methods to visualize atherosclerotic 
plaques/stenoses or occlusions is B-mode ultrasound. One area of particular 
interest is the carotid arteries because its easily accessible and its bifurcation is a 
common site of atherosclerosis (69). The intima media thickness (IMT) of the 
common carotid artery is also used as a surrogate marker for atherosclerosis in 
coronary vessels (70). An increased IMT is predictive of future CVD (71), 
although plaque occurrence seems to be even more predictive for MI (72). 
Ankle-brachial index (ABI) is used to detect peripheral arterial disease (73) and 
a low ABI is predictive of both cardiovascular death and CVD (74). Although 
most studies have evaluated the risk with a low ABI, often defined as a ratio < 
0.9 (73, 75), there is also evidence of an elevated risk for CVD with a high ABI 
>1.4 (76), probably a marker of stiff arteries. Artery stiffness per se is also 
associated with CVD (77) and can be measured in the carotids, the aorta or the 
femoral arteries. 
Another method to detect atherosclerosis is with Electron beam computed 
tomography. This method yields a coronary artery calcium score (78). 
Endothelial dysfunction: is believed to be one of the underlying factors 
involved in the progression towards atherosclerosis (79). Normally the 
endothelium favours a vasodilatory, anti-thrombotic, anti-inflammatory state 
with expression of high levels of nitric oxide (NO) and prostacyclin I2 (PGI2) 
and low levels of reactive oxygen species (ROS) and uric acid. A healthy 
endothelium expresses low levels of vonWillebrand factor (vWf), plasminogen 
activating factor-1 (PAI-1) and P-selectin and also low levels of intercellular 
  13 
adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-
1). An activated/dysfunctional endothelium upregulates ICAM-1 and VCAM-1 
to facilitate the migration of inflammatory cells across the endothelium, it 
decreases NO and PGI2 to contract the vessels and it upregulates vWf and PAI-1 
for platelet adherence and activation (80). 
Elevated levels of ICAM-1 have in the general population been associated with a 
higher risk of future myocardial infarction (MI), angina pectoris and coronary 
death (81). VCAM-1 levels are higher in persons with established atherosclerosis 
(82) and they are also associated with CVD in SLE patients (83, 84). High levels 
of vWf are associated with MI (85), stroke (86) and peripheral arterial disease 
(87).  
VEGF, the growth factor for the endothelial cells, is also more abundant in both 
the atherosclerotic plaque and in the circulation of patients with atherosclerotic 
lesions (88, 89). 
Other methods to measure the endothelial function are various tests of vascular 
reactivity, where flow- mediated dilatation (FMD) is the most used test because 
of its non-invasive approach (90, 91). Endothelial function, as assessed with 
FMD, seems to be impaired in a variety of systemic autoimmune diseases (92). 
 
2.3 MICROCIRCULATION:  
The microcirculation refers to arteries with the smallest resistance, arterioles, 
capillaries, and venules. Whereas the capillary network is essential for the 
exchange of nutrients and gas between blood and tissue, arterioles are involved 
in blood flow regulation (93). In the skin, the microvasculature also represents 
the main organiser of for thermoregulation (94) 
Alterations in microcirculatory blood flow or capillary structures have been 
identified in several disease processes such as sepsis (95) diabetes (96, 97), 
cardiovascular disease (98) and SSc (99).  
These alterations may have different pathogenic background but they can 
nevertheless all lead to a reduced blood flow, defect tissue oxygenation, 
decreased tissue nutrition or capillary rarefaction (93). 
In the normal population, 40% of the patients with symptoms of heart ischemia, 
have normal coronary arteries. In 1985, Cannon and Epstein introduced the term 
‘microvascular angina’ for this patient group, in view of what appeared to be an 
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enhanced sensitivity of the coronary microcirculation to vasoconstrictor stimuli 
associated with a limited microvascular vasodilator capacity (100). This patient 
group consist of mostly women. Although the underlying pathogenesis is 
unknown; some of these patients have signs of endothelial dysfunction, and a 
scattered pattern on myocardial scinthigraphy (98).  
The coronary microcirculation can be indirectly studied during coronary 
angiography, but this is an invasive method. The cutaneous circulation has 
therefore emerged as an accessible and potentially representative vascular bed to 
examine the mechanisms of microcirculatory function and dysfunction (93).  
The cutaneous vasculature is organized as two horizontal plexuses in the dermis: 
the upper network (from which capillary loops arise) located in the papillary 
dermis is connected to a lower dermal–hypodermal network through ascending 
arterioles and descending venules.  Arteriovenous anastomoses, which bypass 
the capillary circulation, are found in glabrous skin especially in the digits. There 
is a major neural influence on skin microvascular reactivity, an this is one reason 
why the skin contains a higher density of nerve fibers than most other tissues. 
(93).  
 
Structural changes in the capillary vasculature are easy to examine in the 
nailfolds, where the capillaries lie close to the surface arranged in symmetrical 
loops. This can be done with a simple magnifying device such as a dermatoscope 
or an ophthalmoscope, together with some immersion oil. More detailed studies 
of vessel morphology can be performed with a wide-field stereomicroscope or 
with a digital videocapillaroscope. Outside the periungueal region, where 
capillaries are perpendicular to the skin surface, videocapillaroscopy can be used 
to assess capillary density and capillary recruitment. Nailfold capillaroscopy is 
the most used method to evaluate the microcirculation in SSc (101).  
Figure 2: Digital vessel with 
afferent and efferent parts. 
Collaterals in between. 
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Other techniques such as orthogonal polarization spectral imaging (OPS) and 
sidestream dark-field imaging (SDF) provide images of the microcirculation 
with a high level of contrast on organs covered by a thin epithelial layer. OPS 
and SDF are used when assessing the microcirculation in organs during surgery 
and especially SDF has emerged as a non-invasive tool to examine the 
microcirculation in intensive care patients, often in the sublingual mucosa.(102) 
Laser Doppler flowmetry (LDF) is commonly used to assess microvascular 
reactivity, often together with iontophoresis or in combination with post 
occlusive reactive hyperaemia. Iontophoresis is a non-invasive method of 
distributing drugs trough the dermis based on the transfer of charged molecules 
using a low-intensity electric current. LDF, together with iontophoresis of 
acetylcholine and sodium nitroprusside is used to assess microvascular 
endothelial function (93). 
2.4 CARDIAC FIBROSIS: 
The cardiac fibroblasts are responsible for maintaining the delicate matrix 
network of the heart; the epimysium, enveloping the whole cardiac muscle, the 
perimysium, surronding bundles of muscle fibres and the endomysium, that 
surrounds single myocytes. Cardiac fibrosis is associated with an increased 
deposition of matrix proteins in the myocardium. It could be either a ”reactive 
interstitial fibrosis” that describes an expansion of extracellular matrix in the 
absence of cardiomyocyte loss, or “reparative fibrosis”, that replaces dead or 
damaged myocardial cells with myofibroblast (i.e. scarring) (103).  
The collagen content increases with age and the endo-and perimysial fibers 
become thicker. This leads to a stiffer ventricular wall and diastolic dysfunction.  
In the Framingham heart study there was an age-dependent increase in these two 
measurements (104). 
Myocardial fibrosis is normally a slow process that is more prominent in older 
ages. In an adult healthy heart almost 75% of the myocardial tissue volume is 
composed by myocytes, but myocytes account for only about 30-40% of the total 
number of cells in the heart. Endothelial cells, fibroblasts and pericytes are 
abundant in the myocardium; small numbers of macrophages, mast cells and 
dendritic cells are also present in the perivascular and interstitial space (103). 
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2.5 METHODS TO STUDY THE HEART: 
 
ECG: The ECG device detects and amplifies the repetitive waves of electrical 
changes on the skin that are generated when the heart muscle progress the 
depolarisation wave from the sinoatrial node, through the atrium, atrioventricular 
node and then spread over the ventricles, before the next repolarization starts. 
The ECG technique was introduced around 1870, but it became clinically 
available 1901 by Willem Einthoven, who was later awarded the Nobel Prize for 
this invention. He also gave name to the different parts of the ECG: P, Q, R, S, 
T, U-waves (105). 
The 12-lead ECG is commonly available and widely used in most clinical 
settings. ECGs can visualize the electrical axis of the heart, the cardiac rhythm, 
disorders of the activation sequences, signs of hypertrophy and signs of 
myocardial ischemia. 
Holter-ECG: is an ambulatory device used to monitor heart rhythm for longer 
periods of time, most commonly for 24-hours. For practical reason only a few 
electrodes are used and therefore Holter recordings don’t reflects as many parts 
of the heart as 12-lead ECGs. The advantage of this method is to detect 
sporadically emerging arrhythmias such as extrasystoles or paroxysmal atrial 
fibrillations and also to get an association between patient-recorded symptoms 
and ECG-alterations (106). 
 
Echocardiography: By combining the function of ultrasound and Doppler 
techniques it is possible to visualize the heart in real time. Echocardiography can 
give both a multidimensional picture of the structure and morphology of the 
heart and the function of the chambers and heart valves. It is possible to measure 
the dimensions of the atria and ventricles, the thickness of the septal and inferior 
walls, assess the structure and the function of the cardiac valves, and visualize 
the amount pericardial effusion, -if any (107)  
The left ventricular systolic function is commonly measured by determination of 
the ejection fraction (EF). This can be done by a variety of methods. In this 
thesis we used a method based on visual estimation and AV plane displacement 
(108).  
               Diastole is the time between the closure of the aortic and the closure of the 
mitral valves. It can be divided into four different phases. The first phase is the 
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time from the aortic valve closure till the mitral valve opens. It is called the 
isovolumetric relaxation time (IRVT). Thereafter come the rapid filling, the slow 
filling and then the atrial contraction. The diastolic function is determined by a 
combination of measurements from the inflow over the mitral valve; the 
maximal velocity during the rapid filling (E), the maximal velocity during the 
atrial contraction (A), E/A, how rapidly flow velocity declines in early diastole 
(E-wave deceleration time = DT), the IVRT or the  E/e´ratio (107) 
The cardiac valves can be studied both structurally and functional with colour 
Doppler, and regurgitations can be graded from the spectral Doppler intensity. 
Echocardiography is commonly used in SSc as a screening method for 
pulmonary hypertension. It is possible to calculate an estimated systolic 
pulmonary arterial pressure by the formula: 4x (v maxTI)2 +PHF, where v maxTI  
is the maximal velocity of the tricuspidalis insufficiency and PHF is the pressure 
in the right atrium(107).   
   Annual screening for PAH is recommended from both American Heart 
Association and the European Society of Cardiology. The need for screening 
was highlighted in a study by Humbert et al, who examined 32 patients with 
PAH, 16 were diagnosed after a regular screening program and 16 patients were 
diagnosed in routine care. After 8 years 81% of the patients, diagnosed in 
“routine care” were dead, compared to 31% of the patients in the regular 
screening program (109). 
 
2.6 BIOMARKERS FOR CARDIAC DAMAGE: 
 
Cardiac Troponins (cTn):  
The troponin complex is composed of three protein subunits; troponin T, I, and 
C. But only troponins T and I have unique cardiac isoforms. Cardiac troponins 
are bound to actin in cardiac myofibrils, and only a small fraction of these 
proteins are soluble in the cytoplasm. Ischemia is thought to alter cell membrane 
integrity, causing rapid depletion of the soluble cytoplasmatic pool, followed by 
larger and more sustained release of troponin into the circulation. Because of 
their specificity for cardiac tissue, cardiac troponins have become the main 
biomarkers for detection of myocardial infarction (110). 
Cardiac troponins T (cTnT) and I (cTnI) provide largely identical information, 
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but while cTnT assays is produced by a single manufacturer, multiple 
manufacturers make cTnI assays and each manufacturer uses different antibody 
pairs, so assays are not comparable (110). 
There are studies that indicate that cTnI is to a less extent influenced by impared 
renal function (111) or damaged skeletal muscle (112). 
During the last years new high sensitivity (hs)-cTn assays for the detection of 
cardiac troponins have become available (113). These have improved the 
sensitivity but at the cost of lower specificity. Although an elevated cTn mirrors 
a myocardial injury, the underlying mechanisms are not always an acute 
myocardial infarction. An elevated cTn could be due to previous myocardial 
damage or stressful situations such as sepsis, pulmonary embolism, pulmonary 
hypertension, infiltrative diseases such as sarcoidosis or amyloidosis, cardio 
toxic drugs etc (114). With the new hs-cTn assays it is also difficult to determine 
what is a “normal value”.” When cTns are examined in older (>70 years), 
presumably healthy, persons the cut-off for the 99% percentile is higher than in 
younger individuals, but it still remains as strong predictor for mortality (115, 
116).  
 
NT-proBNP:  
In order to counterbalance the vasoconstrictive and sodium retaining 
neurohormones, which are released from the renin angiotensin aldosterone 
system (RAAS), the heart produces vasodilating antiproliferative hormone like 
substances called natriuretic peptides (NP). The main natriuretic peptides 
produced in the heart are atrium natriuretic peptide (ANP) and brain natriuretic 
peptide (BNP). Both peptides are produced in the atria, but in a chronic stressful 
situation such as heart failure, the ventricular myocytes are also able to 
upregulate their production of BNP (117). 
Levels of NPs are elevated in disorders with salt and fluid overload and when 
atrial or ventricular wall tension is increased. They regulate blood pressure and 
fluid balance, increase endothelial permeability and have an important role in the 
body’s defence against mineralocorticoid-and salt- induced hypertension and 
plasma volume expansion. They lead to an increased cardiac output and to 
improved diastolic function. BNP are stored in secretory granulae and it is as a 
prohormone called proBNP. When released to the blood it is cleaved to BNP and 
NT-proBNP. NT-proBNP has a longer half- life, making it suitable for detection 
in the clinic, but both hormones are useful in the detection and follow up of heart 
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failure (117).  
Although mainly used as a marker of heart failure, higher levels of NT-proBNP 
can also be seen in other conditions such as left ventricular hypertrophy, 
tachycardia, pulmonary hypertension, myocardial ischemia, hypoxemia, renal 
dysfunction, advanced age, liver cirrhosis, sepsis and infection(117). Several 
studies have noticed the usefulness of NT-proBNP in screening and follow up 
for patients with SSc-PAH and it is now used in many countries as a “clinical 
routine” test for these patients (118-121) 
 
 
2.7 OTHER BIOMARKERS 
 
Uric Acid: During the last decades uric acid (UA) has been studied as a possible 
biomarker for cardiovascular disease (122). Elevated levels of UA have been 
associated with MI, stroke and heart failure (123, 124). Although many other 
more established risk factors are associated with higher levels of UA, such as 
kidney disease, obesity, hypertension, there is some evidence that supports a 
causal connection between UA and CVD (122).  
UA is a product of purine metabolism, formed from the breakdown of adenosine 
and guanine. It is produced through the action of the enzyme xanthine oxidase; 
during a process when oxidants are also produced. This could imply that the 
elevated UA only is a sign of enhanced oxidation, but there are several theories 
suggesting a harmful effect of UA per se. Local and circulating UA levels are 
influenced by tissue oxygenation and hemodynamic aspects as well as by 
dietary, genetic, drug-related, and renal factors. It seems like UA can act both as 
an antioxidant or oxidant depending on the environment.  UA mediates 
endothelial dysfunction by decreasing NO and induce vascular smooth muscle 
cells via a pathway involving PDGF. UA can also accumulate inside 
atherosclerotic lesions (125) and elevated UA is seen in both idiopatic (126) and 
SSc-PAH (127).  
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Cystatin C: Cystatin C is a reversible inhibitor of cysteine proteinases that is 
produced by most cells. It is freely filtered at the glomerulus and is then 
reabsorbed and catabolized in the proximal renal tubules. It is not affected by 
gender or muscle mass, and it is sensitive to small impairments of renal function. 
It is therefore believed to be a more accurate measure of renal function than 
creatinine, especially when the loss of renal function is moderate (128). In recent 
years, cystatin C has been reported to be a prognostic marker for CVD in the 
general population even after adjustment for renal function (129).  
 
 
2.8 TRADITIONAL RISK FACTORS: 
The classical traditional risk factors for cardiovascular disease were described in 
the large epidemiological study in Framingham 1971. The original Framingham 
risk factors are age, male gender, smoking, family history, diabetes, hypertension 
and hyperlipidaemia (130) 
There are only a few studies addressing the lipid profile in systemic sclerosis. 
Most of these studies did not find any differences in lipid profile between 
patients and controls but there are a few reports of higher levels of triglycerides, 
lower levels of high density lipoprotein (HDL) (131), higher sensibility to 
oxidation of low-density lipoprotein (LDL)(132) and higher levels of lipoprotein 
a (Lp(a)) (133).  
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3 CARDIOVASCULAR DISEASE AND 
ATHEROSCLEROSIS IN SYSTEMIC SCLEROSIS 
 
3.1 THE HEART IN SYSTEMIC SCLEROSIS:  
Clinical manifest/symtomatic cardiac disease has a prevalence between 15-35% 
in SSc, but subclinical cardiac disease is found in the majority of patients (134). 
When clinically evident, cardiac manifestations are associated with a poorer 
prognosis and mortality (135). All structures of the heart can be involved with 
manifestations such as pericardial effusion, arrhythmias, conduction system 
defects, valvular impairment, myocardial ischemia, myocardial hypertrophy and 
heart failure (136). 
In autopsy studies d´Ángelo (137) and Bulkley (138) found patchy myocardial 
fibrosis with a characteristic distribution of the lesions in the myocardium that 
did not correspond to the regional blood supply of a single coronary artery. The 
coronary arteries in these autopsy cases were also strikingly unaffected.  In 
another autopsy study (139), eight SSc patient, all with previous known heart 
disease (six of them died of sudden death) had distinct morphological 
abnormalities in the conduction system, especially in the sinus node. Narrowing 
and platelet-fibrin clots in the small coronary arteries supplying these regions 
were also detected. This lead to the theory of a “myocardial Raynaud´s 
phenomenon”, according to which damage to the heart is caused by repeated 
ischemia-reperfusions. This theory has been tested in several cold-provocative 
studies (140, 141). 
Myocardial biopsies on the other hand have been undertaken in patients with 
cardiac failure and they often show an inflammatory pattern, i.e. evidence of 
myocarditis. Most are case reports or case series (142, 143) but in one study 
comparison between idiopathic PAH and SSc PAH showed a marked 
inflammation in myocardium of SSc-patients (144). 
Clinical myocarditis is commonly associated with skeletal muscle diseases or 
scleroderma-myositis overlap (145, 146). Pericarditis is prevalent in 30-75% of 
patients, but it is often asymptomatic (147).  
Cardiac MRI has emerged as a sensitive technique to identify cardiac disease 
in SSc and it has identified a high prevalence of disease, which correlates with 
previous autopsy studies. Gadolinium-delayed contrast enhancement is used to 
evaluate myocardial fibrosis while T2-weighted imaging identifies inflammatory 
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lesions (148-150). 
 
Left ventricular systolic or diastolic dysfunction can occur many years before 
becoming clinically evident (147, 151). Systolic dysfunction seems to be less 
common than diastolic dysfunction (152-156) and it mainly occurs together with 
and likely because of concomitant coronary artery disease or systemic 
hypertension (152, 157). One study used a newer strain method to detect LV 
systolic impairment and found LV systolic dysfunction in even in patients with a 
normal LVEF (158). When a low LVEF is present, it seems to be associated with 
clinical characteristics such as myositis, digital ulcerations, male gender, older 
age and it is more common in patients who are not treated with calcium-channel 
blockers (159). 
 
LV diastolic dysfunction has been subject of numerous studies in SSc because of 
the assumption that it mirrors myocardial fibrosis. The prevalence of diastolic 
dysfunction in SSc, measured with conventional Doppler echocardiography, is 
20-40% (153, 156, 160, 161), and with tissue Doppler as high as 60% (162, 
163),  but there are also studies, including ours, were no difference in diastolic 
dysfunction between patients and controls were detected, especially after 
adjusting for other factors (164, 165). Although diastolic dysfunction can be 
detected with several measurements on echocardiography, Lee et al found that 
the E/é ratio was more sensitive than E/A ratio in SSc patients (166). 
 
Right ventricular systolic and/or diastolic dysfunctions are also impaired in SSc 
(167-169), and seem to exist despite no underlying PH or LV dysfunction (156, 
164, 170). Right ventricular dysfunction seems furthermore to be more 
pronounced in patients with SSc-PAH than idiopatic PAH (171, 172). 
Echocardiography is used as a screening method for PH in SSc, and an ePAP>36 
mmHg is a predictor of mortality in SSc patients (173). Although right heart 
catheterisation remains as the golden standard for the detection of PH, 
echocardiography, especially in combination with other test such as pulmonary 
function test and biomarkers seems to be reliable for screening (174). 
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There are not many studies addressing valvular defects in SSc. In autopsy 
studies, shortening of the chordae tendineae of the mitral valve has been noted, 
as well as mitral and tricuspid valve vegetations (138). Even if there are several 
echocardiographic studies in SSc, there are only a few reports on valve 
regurgitations or stenosis. In one small study including 11 patients with 
progressive systemic sclerosis, mitral valve prolapse was recorded in 2 patients 
(175). Kazzam et al examined 30 patients and 30 controls and found mitral 
regurgitation in 67% of the SSc patients versus 15% of the controls (176). In a 
study comparing SSc-, myositis-, SLE- patients and controls, patients with SSc 
had the highest frequency of mitral and/or aortic regurgitation, 10% versus 1.7% 
in SLE and 0% among myositis patients and the controls. 11,3% of the SSc 
patients and 18,7% of the SLE patients had tricuspidalis regurgitations; this 
finding was associated with a higher right systolic pulmonary pressure (177). I a 
large study consisting of 570 patients, 7.2% had mitral regurgitation, and 2.4% 
aortic regurgitation (161) 
 
Conduction defects and arrhythmias:  
An abnormal ECG is present in 25-75% of patients with SSc and is considered 
an independent predictor of mortality (178, 179). In a EUSTAR database study, 
26% of the deaths were due to cardiac disease and about half of these were due 
to malignant arrhythmias (135)(Tyndall). In another study cardiac arrhythmias 
were one of seven variables predictive for mortality, with a hazard ratio (HR) of 
2.8 (180).  
In a study by Ferri et al, ventricular arrhythmias were found in 90% of SSc 
patients with Holter ECG, but they did not correlate with clinical variants or with 
other clinical symptoms or signs of the disease. Abnormal ventricular 
arrhythmias were more likely in patients with echocardiographic abnormalities 
(181). A large observatory study reported that severe cardiac arrhythmias with a 
poor prognosis were significantly more frequent in patients with concomitant 
skeletal and cardiac muscle involvement (146). Some studies have also 
demonstrated impairment of heart rate variability and turbulence as a measure of 
autonomic nervous system dysfunction (182).  
Conduction alterations are more prevalent in SSc than controls (183). The most 
common alteration seems to be left bundle branch block (LBBB), but AV-
conduction defects and right bundle branch block (RBBB) are also present. 
RBBB are predictive for mortality in early SSc (184) 
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QTc prolongation, which can lead to life-threatening tachy-arrhythmias, has also 
been reported in SSc patients (178). 
Follansbee et al found septal infarction pattern in 10 of the SSc patients but none 
of the controls. A more detailed examination was done in 6 of these patients and 
all had septal thallium perfusion abnormalities, but normal coronary angiography 
(183). 
 
 
3.2 MACROVASCULAR DISEASE AND ATHEROSCLEROSIS IN 
SSC 
 
During the last years, there is emerging evidence of a high prevalence in SSc of 
disease manifestations commonly associated with atherosclerosis such as 
myocardial infarction (MI), peripheral vascular disease (PVD) and stroke.  
During 2012-2013 there were 3 population-based studies addressing this matter 
from three different continents. In a study from Taiwan, the hazard ratio (HR) for 
myocardial infarction (MI) in SSc was 2.45 (185) and in a study from Boston, 
USA, the HR was 1.8 for MI, 2.6 for stroke and 4.35 for PVD (186). In a study 
from Australia, the odds ratio (OR) for coronary heart disease in SSc was 
between 1.9 and 3.2 depending on control group and adjustment for other factors 
(187). 
Although the underlying factors still are under evaluation there is some evidence 
of an enhanced atherosclerosis in SSc patient as compared with controls, but the 
studies are conflicting and differ in selection of both patients and controls (table 
below). Two meta-analyses have concluded in favour of enhanced 
atherosclerosis (188, 189).  
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Table: Atherosclerosis in systemic sclerosis: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Referenses:(190-204) 
	  
	   1	  
Table 4: A selection of previous studies of atherosclerosis in SSc vs controls: 
 
 Characteristics patients Characteristics controls IMT (mm) and/or Plaque (%) 
Lekakis et al 
1998 
N: 12, age: 49, female 100% 
dcSSc 100% 
No ACA 
N: 12, age: 49 female 100% 
Healthy, no ECG 
abnormalities  
0.83 ± 0.3 patients 
0.46!± 0.2 controls 
é  
P=0.002 
Stafford et 
al 1998  
N: 20, age: 64, female 90%  
lcSSc 90% dcSSc10% 
 
N: 20, age: 66 
Other reumatic diseases 
(excluding SLE and 
vasculitis) matched for age, 
sex, smoking, diabetes, and 
hypertension 
CCA diameter  cm/m2 
43.3 patients 
44.8 controls 
   
çè 
p=0.7 
Cheng et al. 
2003  
N: 53, age 55, females 81% 
 
N: 20, age 43 females 80% 
Patients undergoing surgery, 
no cardiac disease 
0.68 ± 0.27 (lcSSc) 
0.62±0.20 (dcSSc) 
0.63 ± 0.20 controls 
çè 
P = 0.090 
 
Szucs et al. 
2007  
N: 29, age 52 
Excl: previous CVD, 
diabetes, smokers, BMI>30, 
vasculitis, infection, renal 
failure. 
N: 29, age 49 
Health staff and patients 
from the hospital, matched 
for age, sex and traditional 
risk factors 
0.67±0.26 patients 
0.57±!0.09 controls  
 
çè 
P = 0.067 
Kaloudi et 
al. 2007  
 
N: 66, age 62 
55 lssc, 11 dssc 
Excl: diabetes, smokers, 
renal failure. 
N: 20, age 58 
Selection not specified 
0.90 ± 0.04 (lcSSc) 
0.87 ± 0.04  (dcSSc) 
0.69 ± 0.01 controls 
 
é 
P < 0.01 
 
Bartoli et al  
2007 
N: 53, age 60 females 89% 
lcSSc 85% dcSSc 
 
N: 53 age: 56, females 93% 
Excl: previous CVD 
0.85 ± 0.03 patients 
0.68 ±0.01 controls 
 é 
P<0.03 
Bartoli et al. 
2007  
 
N: 35, age: 61  
Excl: diabetes, kidney 
disease, tx: steroides or Cyc. 
N: 20 age not specified 
Health staff, comparable age, 
sex, traditional risk factors. 
0.93 ± 0.29 patients 
0.77 ±0.13 controls 
 
 é 
P<0.003 
Zakopoulos 
et al. 2003  
N: 40, age not specified 
 
N: 45 age not specified 0.69±0.25 patients    
0.59±0.1 controls 
çè 
NS 
Roustit et al. 
2008  
N: 42, age 51 
Excl: smoking, diabetes, 
severe disease (Cardiac or 
pulmonary failure, IHD) 
N: 33, age 52  
Asked by advertice in paper 
0.53±0.23 patients 
0.51±0.11 controls                  
 
çè 
p=NS 
Hettema 
2008 
N: 49, age 55, females 84% 
lcSSc 82%, dcSSc 8% 
N: 32, age 51, females 91% 
Selection not specified. 
0.69 
0.68  
çè 
p = 0.067 
Ho et al. 
2000  
  
N: 54, age: 57, female 93% 
lcSSc, dcSSc 
N: 43, age: 53, female 81% 
Population-based with 
comparable age, gender. 
Excl: Raynaud´s 
phenomenon, other 
Rheumatic diseases 
64% patients 
35% controls  
 
é 
p= 0,007 
 
Sherer et al. 
2007  
 
N: 44, age: 62, gender ?  
lcSSc 86%, dcSSc 14% 
ACA 50% 
N: 32, age: 60, gender ? 
Age-matched 
IMT > 0,9 mm: 
43% patients  
28% controls 
é 
P=0,026 
 
Tsifetaki et 
al 2010  
N: 60, age 56, females: 92% 
lcSSc 
N: 51, age 51, females 88% 
 
0,77 ± 0,2 patients 
0,59 ± 0,14 controls 
 
é 
 
p<0,0001 
 
Excl: history of CVD, hypertension, smokers, diabetes, 
hypothyroidism, liver or kidney diseases, Cushing’s 
syndrome, BMI > 30, receiving medications affecting lipid 
metabolism 
Vettori et al. 
2010  
 
N: 50, age 52, females 92% 
lcSSc 70%, dcSSc 30 % 
ACA 52% 
N: 41, age: 52, females 90% 
Fibromyalgia or 
osteoarthritis patients 
matched for age and sex. 
0,61 ± 0,24 patients 
0,65 ± 0,17 controls 
IMT >9 and/or plaque 
28% patients 
9.8% controls 
çè 
P>0.05 
 
 é 
P=0.004 
Schiopu et al 
2013 
N: 46, age: 49, females 100% 
lcSSc 50% dcSSc 50% 
N: 46, age: 49,females 100% 
Matched for age and 
ethnicity, randomly selected 
from a previous study 
consisting of 167 controls, 
reported healthy. 
0.59±0.13 patients 
0.56±0.13 controls 
plaque: 
46% patients 
20% controls 
çè 
P=0.07 
é 
P=0.01 
N: numbers, SSc: Systemic sclerosis, IMT: intima media thickness,  dcSSc: diffuse cutaneous SSc, lcSSc: limited cutaneous SSc, 
ACA: anticentromere antibodies, SLE: systemic lupus erythematosus, CCA: common carotid arteries, CVD: cardiovascular disease,  
IHD: Ischemic heart disease, BMI: body mass index 
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3.3 MICROVASCULAR DISEASE IN SYSTEMIC SCLEROSIS: 
1975 Campbell and LeRoy presented their “vascular hypothesis”, which 
suggested that microvascular disease was a fundamental part of the pathogenesis 
of scleroderma (205). This hypothesis has lead to a change in the definition of 
SSc criteria (11) and also to development of more vascular animal models 
addressing the pathways involved in the progression to both vasculopathy and 
fibrosis (37, 206, 207).  
Raynaud´s phenomenon (RP) is one of the most common disease manifestations 
in systemic SSc, affecting >90% of all patients. In most cases it also precedes the 
other disease manifestations by several years. In addition to an injury of the 
endothelium, decreased release of vasodilatory neuropeptides from sensory 
nerves and up regulation of vascular smooth muscle receptors that enhance 
vasoconstrictive responses to stress or cold stimuli are implicated in the 
dysfunction leading to RP (32).  
Biopsies from the digits of patients with SSc-RP shows unique changes in 
vascular structure, characterized by intimal thickening, narrowing of the vascular 
lumen and in some cases also microthrombosis (208).  
The structural changes in the capillaries are easily detected in the nail folds of 
SSc patients and a typical scleroderma pattern has been described, which 
includes capillary loss, dilated capillaries, microhemorrages (209). This pattern 
is present in >80% of the SSc patients, but its not unique for SSc. It can 
occasionally be found in other connective tissue diseases, such as mixed 
connective tissue disease (MCTD) or myositis (210). A staging system has been 
developed by Cutolo et al dividing the morphological changes into an early, 
active and late pattern (99). 
The structural changes in the capillaries can be visualised in other sites of the 
body as telangiectasias in the skin or gastric antral vascular ectasias (GAVE) in 
the stomach (32). 
Although the morphological changes in the nailfold capillaries are most studied, 
there are also evidence of impaired capillary blood flow (211) and a reduced 
response to different stimuli with iontophoresis (212). 
The changes in nailfold capillary pattern, especially loss of capillaries, has been 
associated with disease severity (213), an elevated ePAP or PAH (214-216), 
digital ulcers (217), severity of digital ischemia and ACA (218). 
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About 40-50% of the SSc patients develop digital ulcers, usually in the first 5 
years from disease onset (61). Digital ulcers localized on the finger pads can 
leave a pitting scar, which can be seen in 15-30% of the patients. The ulcers take 
3-15 months to heal (219) and are associated with a reduced quality of life, work 
disability (220). Infections, osteitis, gangrene and amputations are some of the 
complications associated with DU in SSc (221). 
Digital ulcers can also bee seen on the dorsum of the hand, often localized on the 
knuckles. These ulcers seem to be more associated with mechanical stress 
because of the tightness of the skin and contractures in this region. Despite this, 
these ulcers reduce QoL just as much (222).  
Digital ulcers have been associated with capillary microscopy findings and 
reduced capillary density is therefore used in two different score system for 
prediction of future digital ulcers (223, 224). Factors associated with digital 
ulcers are many and in several studies discrepant i.e. male gender, dcSSc, ATA 
(52, 219, 225) or lcSSc, and ACA(226, 227) are factors which have been 
positively associated. Because of the discrepant in definition of digital ulcers 
(228), an international group has suggested a method of categorizing ulcers for 
pharmacological studies(229). 
Besides RP and digital ulcers there are two other severe disease manifestations 
where the vasculopathy seems to be of major importance: the scleroderma renal 
crisis (SRC) and pulmonary arterial hypertension (PAH) (32).  
SCR was the major cause of death in SSc about 40 years ago, but since the 
introduction of ACE inhibitors, this disease manifestation is rare (230). SRC is 
typically characterized by a sudden and marked increase in systemic blood 
pressure (although normotensive SRC has been described) and acute renal failure 
(230). The histopathology shows a thrombotic microangiopathic process similar 
to idiopathic malignant hypertension with small vessel changes that predominate 
over glomerular alterations (231). Small vessel thrombi, intimal fibrosis and an 
onion-like appearance around the vessels, which obstruct the lumen, are typical 
for SRC. Even if early treatment with ACE-inhibitors have reduced mortality, 
SRC is associated with significant morbidity and mortality (232, 233) 
PAH is together with pulmonary fibrosis the dominating cause of scleroderma 
related deaths (ref). Despite new PAH treatments during the last 10 years, SSc 
associated PAH still has a more pessimistic prognosis than idiopathic PAH. 
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4 AIMS 
We wanted to examine if SSc patients had more macrovascular disease, 
atherosclerosis and cardiac disease than controls, and also if macro- and 
microvascular disease were associated in SSc patient. 
We specifically aimed to answer the following questions: 
1. Are macrovascular events more common in SSc patients than in controls, 
and if so, what events are more prevalent? 
2. Do Scc patients have more atherosclerosis than controls? 
3. How do traditional risk factors, inflammatory and endothelial biomarkers 
relate to the occurrence of macrovascular disease and atherosclerosis in 
SSc?  
4. Do cardiac rhytm disorders differ between SSc patients and controls?  
5. Do ecocardiographic abnormalities differ between SSc patients and 
controls? Are echocardiographic abnormalities associated with SSc 
subsets? 
6. Are the cardiac biomarkers (cTnI, NT-proBNP) elevated in SSc patients, 
and are they associated with echocardiographic abnormalities?  
7. Are there any associations between macrovascular and microvascular 
disease in SSc? 
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5 METHODS 
5.1 STUDY POPULATIONS 
Studies I-III are cross-sectional case-control studies, including 74% of the known 
prevalent SSc-cases in Stockholm County. Study IV is a cross sectional study 
including 163 consecutive SSc patients. 
 
Studie I-III.  
All participants were >18 years old and recruited from the adult population in 
Stockholm County (N=1 534 272) between August 2006 and December 2009. 
 
Patients:  
Prevalent cases with SSc were identified at the three Rheumatology clinics 
associated with general/university hospitals and from all rheumatologists with 
private practice. All dermatologists, gastroenterologists, specialists in respiratory 
medicine, hand surgeons, cardiologists, vascular surgeons and general 
practitioners were contacted twice and asked to inform us about their patients 
with SSc or suspected SSc. A letter describing features of SSc was attached. 
Through this approach, we identified 149 cases fulfilling the 1980 ARA criteria 
for SSc (7), which corresponds to a prevalence of 97 adult SSc cases/ million. Of 
those 118 patients accepted to participate in the study and were included. Seven 
patients did not complete the cardiovascular examination, and one patient was 
only investigated with carotid ultrasound but not with the heart examination, 
therefore study I consists of 111 patients and study II and III consist of 110 
patients. After permission from the patients not included in the study (26%), 
their medical records were reviewed, and they did not differ from the included 
patients (74%) regarding age, disease duration or severe organ manifestations. 
We also performed a search for the diagnosis M34.0-M34.9 in the Swedish 
inpatient/outpatient registry for persons living in Stockholm between august 
2006 and December 2009. This search identified 235 patients with one of these 
diagnose codes, but earlier studies have demonstrated a high level of 
misclassification in this diagnosis group, with about 50 % of the patients not 
fulfilling the 1980 ARA criteria. (14, 234). 
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Controls:  
Control subjects were recruited from the same population through use of the 
national registration number, which includes date of birth and is coded for sex. 
The sex-matched person with the birth date closest to the patient was contacted 
and asked to participate. A diagnosis of SSc was the only exclusion criteria. 
When the “first choice” declined, the second closest person was asked, until a 
control subject gave his/her consent. In 65 % of the cases, the “first choice 
control” accepted to participate. 110 controls were included, but five did not 
complete the cardiac/carotid examination, thus 105 controls participated in study 
I-III.  
Studie IV 
The 118 patients included between 2006-2009 and 45 patients included between 
January 2010-September 2013 participated in this study. We used the new 
classification criteria for this cohort (11) thus including 11 patients who only 
fulfilled the new classification criteria. The rest of the patients fulfilled both the 
1980 ARA and the 2013 ACR/EULAR classification criteria. Some of the 
patients, who did not want to participate in studies I-III, gave their consent to 
participate in study IV.  
The local Ethics Committee of the Karolinska University Hospital approved the 
studies and all participants gave written informed consent.  
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5.2 DEFINITION OF DISEASE ACTIVITY, SEVERITY, ORGAN 
INVOLVEMENT AND CARDIOVASCULAR EVENTS: 
 
Table 4: European Scleroderma Study Group activity score (235). 
Criteria Point 
mRss >14 1 
Scleredema 0.5 
Deterioration skin* 2 
Digital necrosis (active digital ulcers 
ranging from digital tip infarcts to 
digital gangrene) 
0.5 
Deterioration vascular* 0.5 
Arthritis 0.5 
DLCO<80% of predicted value 0.5 
Deteriotation heart/lung* 2 
ESR >30 1.5 
Hypocomplementemia (Low C3 or 
C4) 
1 
mRSSc: modified rodnan skin score, deterioration*: patient report worsening the last month of these symptoms.  
DLCO: Diffusion capacity of the lung for carbon monoxide. ESR: erythrocyte sedimentation rate. 
A score >2.5 is defined as active disease. 
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Table 5: Medsger Disease Severity scale: (236) 
Organ 
system 
0  1 (Mild) 2 (Moderate) 3 (Severe) 4 (Endstage) 
General  Wt loss 5.0–9.9 kg 
PCV 33.0–36.9% 
Wt loss 10.0–14.9 
PCV 29.0–32.9 
Wt loss 15.0–19.9 
PCV 25.0–28.9 
Wt loss 20.0+, PCV < 
25.0 
Peripheral 
vascular 
 Raynaud 
phenomenon 
requiring 
vasodilators 
Digital pitting scars Digital tip 
ulcerations 
Digital gangrene 
Skin  TSS = 1–14 TSS = 15–29 TSS = 30–39 TSS = 40+ 
Joint/tendon  FTP = 1.0–1.9 FTP = 2.0–3.9 FTP = 4.0–4.9 FTP = 5.0+ 
Muscle  Proximal 
weakness,mild 
Proximal 
weakness,moderate 
Proximal 
weakness,severe 
Proximalweaknesssevere; 
ambulationaids required 
Gastro--
intestinal tract 
 Distal esophageal 
hypoperistalsis: 
small bowel series 
abnormal 
Distal esophageal 
aperistalsis; 
antibiotics required 
for  
Malabsorption 
syndrome; 
episodes of 
pseudoobstruction 
Hyperalimentation 
required 
Lung  DLCO 70–80%, 
FVC 70–80%, rales, 
fibrosis on ograph 
DLCO 50–69%, 
FVC 50–69%, mild 
PH 
DLCO < 50%, 
FVC < 50%, 
mod-sev PH 
Oxygen required 
Heart  EKG conduction 
defect LVEF 45–
49% 
Arrhythmia RVE 
plus LVE, LVEF 
40–44% 
LVEF < 40% CHF, arrhythmia 
requiring Rx 
Kidney  Serum creatinine1.3–
1.6 mg/dL Urine 
protein 2+ 
Serum 
creatinin1.7–2.9 
Urine protein 3–4+ 
Serum creatinine 
3.0+ 
 
Dialysis required 
 
Wt: weight, CHF, congestive heart failure; DLCO, diffusing capacity for carbon monoxide, % predicted; ECG, 
electrocardiogram; FVC, forced vital capcity, % predicted; FTP, fingertip-to-palm distance in flexion; LVE, left 
ventricular enlargement; LVEF, left ventricular ejection fraction; PCV, packed cell volume (hematocrit); RVE, right 
ventricular enlargement; TSS, total skin thickness score.  
We omitted the joint/tendon and muscular scores due to lack of data regarding 
these items. 
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Organ involvements were defined as:  
Skin score: measured by modified Rodnan skin score (237). This is a method of 
manually measure the skin by palpation the skin to assess the structure. A scale 
from 0-52, where 0 is normal structure and 3 is adhered to the underlying tissue. 
Skin thickness is measured at 17 sites. 
Suspected pulmonary hypertension (sPH): tricuspidalis V-max >2.9m/s on 
Doppler ultrasound.  
Pulmonary fibrosis: signs of fibrosis on X-ray or high-resolution computed 
tomography (HRCT). HRCT was performed in 90% of the patients.  
Myositis: muscular weakness and elevated creatine kinase (CK) and signs of 
inflammation on magnetic resonance imaging (MRI), electromyography (EMG) 
or muscle biopsy.  
Arthritis: swollen joints on examination or arthritis documented in the journals.  
Kidney involvement: a history of scleroderma renal crisis or >1 on the Medsger 
scale for kidney damage 
Digital ulcers: a history of digital ulcers documented in the journal or present at 
inclusion 
Calcinosis: calcium deposits in the skin, observed at inclusion or vizualised on 
X-ray.  
Raynauds Phenomenon: Self reported, with at least a 2-phase colour change in 
fingers consisting of pallor, cyanosis and/or hyperemia in response to cold 
exposure or emotion. 
Scleroderma Renal Crisis: A sudden and marked increase in systemic blood 
pressure and acute renal failure.   
Ischemic arterial events (IAE) were defined as: 
Ischemic heart disease (IHD): myocardial infarction (confirmed by 
electrocardiography and a reversible rise in plasma creatine kinase, muscle and 
brain fraction (CK-MB) or troponin T) or angina pectoris (confirmed by an 
exercise stress test).                                                                                      
Ischemic cerebrovascular disease (ICVD): cerebral infarction (confirmed by 
computed tomography) or transitory ischemic attacks (TIA, defined as transient 
focal symptoms from the brain or retina with a maximum duration of 24 hours).        
Ischemic peripheral vascular disease (IPVD): intermittent claudication + 
ankle-brachial index (ABI) <0.9 or peripheral arterial thrombosis/embolus 
(confirmed by angiogram or Doppler flow studies). 
Any ischemic arterial event includes 1 to 3 above. 
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5.3 ASSESSMENT OF ATHEROSCLEROSIS, HEART RHYTHM, 
HEART FUNCTION AND MICROVASCULAR STRUCTURE:  
Study I:  
Carotid ultrasound: 
The left and right common carotid arteries and bifurcation areas were scanned 
for presence of plaque and images for IMT measurements were received using a 
duplex scanner (Siemens Acuson Sequoia, Mountain View, CA, USA) with a 
7.0 MHz linear array transducer. Scans were digitalized for offline analysis. The 
subject’s head was tilted to get the picture of the common carotid artery (CCA) 
just proximal to the bulb placed horizontally across the screen. Pictures were 
frozen synchronously with the R wave on the electrocardiogram.  
The IMT was defined as the distance between the leading edges of the luminal 
echo and the media/adventitia echo. The IMT was calculated as the intima-media 
area divided by the measured length (10mm) on one scan.  
Plaques were defined as a local increase in wall thickness of >1 mm and 100% 
increase in wall thickness compared to the adjacent wall. 
Ankle-brachial index: 
The study persons were placed in a supine position. The highest systolic pressure 
obtained in arteria tibialis posterior or (if tibialis posterior was inaccessible) in 
arteria dorsalis pedis for each foot were divided by the highest brachial systolic 
pressure to obtain an ankle-brachial pressure ratio (ABI). 
 
Study II:  
Standard and Holter ECGs: 
All patients and controls underwent a standard 12-lead ECG. The first 
participants (49 patients, 42 controls) were investigated at the Department of 
Clinical Physiology, Karolinska University Hospital; they underwent a 22–24-h 
ECG Holter recording (Aspect, Danica Biomedical AB, Borlänge, Sweden). The 
remaining participants (61 patients, 63 controls) were investigated at Aleris 
FysiologLab, Sophiahemmet; they were not subject to Holter tracings. A single 
experienced reader interpreted the recordings without knowledge of patient/ 
control status or other test results. 
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Atrioventricular (AV) and intraventricular (IV) conduction defects were defined 
according to the Minnesota Code Manual (238) Left axis deviation in the 
horizontal plane was defined as an electrical axis between 0 ̊ – 90 ̊. Left 
ventricular (LV) hypertrophy was defined as an R wave inV5 ≥26 mm or R 
wave in V5 plus an S wave in V1 ≥35 mm, ventricular activation time in V5 ≥ 
0.05 s, and ST-T depression in V4–V6. ST segment depression was defined as > 
1 mm horizontal or down-sloping depression. 
Abnormalities on Holter recordings were defined as:  
Ventricular tachycardia, complex ventricular ectopic beats or solitary ventricular 
ectopic beats > 100 for subjects below 50 years of age or > 200 for subjects over 
50 years of age. Supraventricular tachycardia (SVT) was considered abnormal 
for subjects over 50 years of age if > 10 beats, or if more than two episodes/24 h. 
In subjects aged < 50 years, the presence of any SVT was considered abnormal. 
Solitary supraventricular beats were considered abnormal if > 1000 in subjects 
over 60 years of age, > 100 in the 40–60-year age group and > 10 in subjects 
under 40 years of age. 
 
Study II and III 
Echocardiography: 
  We used an Acuson Sequoia (Mountain View, California, USA) with a 2.5 or 3.5 
MHz transducer or a GE Vingmed system 7 (Horten, Norway).  
  Two-dimensional measures were taken as recommended by the American 
Society of Echocardiography (239). Measures of wall thickness and left 
ventricular(AV) plane displacement (240). Briefly atrioventricular plane 
displacement was measured from the apical 4 and 2-chamber views, the M-mode 
cursor was placed at the septal, lateral, anterior and posterior border of the LV 
AV plane (mitral ring) and at the AV plane of the right ventricular free wall. The 
mean AV plane displacement was the average calculated from three heart cycles 
from the four different M-mode positions.  
  The valves were studied carefully for valve thickening and other malformations. 
Doppler and colour Doppler was used to assess valvular stenosis and/ or leakage. 
Regurgitations were graded from the spectral Doppler intensity, the width of the 
colourjet at the base and the appearance of the colour Doppler jet. Regurgitation 
was graded from 1-4 where 1 is mild and 4 severe and regurgitation was 
considered present if it was grade 1 or more. Valvular abnormalities were 
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classified as either abnormal localized echodensity adjacent to valve leaflets or 
valve thickening.  
  Pulmonary artery pressure was estimated by continuous wave Doppler 
measurement of the peak systolic velocity of the tricuspid regurgitation. We used 
the following criteria for PH: 
1. Tricuspid regurgitation velocity > 2.9 m/s, corresponding to an estimated 
pulmonary artery pressure (ePAP) > 34 mmHg at rest with or without 
additional echocardiographic parameters suggesting PH like a dilated right 
ventricle (RV) and impaired RV function.  
2. Tricuspid regurgitation velocity < 2.9 m/s but additional echocardiographic 
parameters suggesting pulmonary artery hypertension. In the absence of 
tricuspid regurgitation pulmonary artery pressure was considered normal. RV 
function was considered abnormal if the free right chamber wall AV 
movement was < 17 mm. Tissue Doppler measurement were made at the 
septal basal segment of the left ventricle and the systolic velocity and the 
diastolic E and A wave velocities were measured. 
 
Study IV 
 
Widefield nailfold capillaroscopy: 
A stereo-zoom microscope instrument (Olympus) set at 20 times magnification 
and equipped with a transparent ruler in one of the eyepieces was used. All 
nailfolds except the thumbs were examined for presence of microhemorrhages, 
enlarged capillary loops and avascular regions. The capillary density (number of 
capillary loops/3mm) was defined as the mean capillary density in the distal row 
in the center of the fourth finger on both hands, because the fourth fingers are 
reported to be the best evaluable fingers (241). Enlarged capillary loops were 
defined as >4 x ordinary capillaries and avascular areas were defined as a lack of 
>2 capillary loops (242). 
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Figure 4: Nailfold capillary findings in a patient with SSc (A) and a healthy 
individual (B). The photos are provided by Marie Wildt, Department of 
Rheumatology, Skåne University hospital, Lund. 
 
Laboratory parameters: 
Paper I: High-sensitivity C-reactive protein (hsCRP), a-1 antitrypsin, 
orosomucoid and fibrinogen were measured using BN ProSpec System (Dade 
Behring, Deerfield, IL, USA). Intercellular adhesion molecule 1(ICAM-1), 
vascular cell adhesion molecule 1(VCAM-1), interleukin 6 (IL-6) and vascular 
endothelial growth factor (VEGF) were analysed by sandwich ELISA kits 
(DY720, DY206, DY137 and DY293B, R & D Systems, Minneapolis, MN, 
USA). Cut-off values were 15 pg/mL for ICAM-1, VCAM-1 and VEGF and 6 
pg/mL for IL-6. von Willebrand factor (vWF) was measured by sandwich 
ELISA (Dako, Glostrup, Denmark) [16]. 
Paper I and III: Cystatin C (reagent: 1014, Gentian, Moss, Norway) was 
analysed on an Architect Ci8200TM analyser (Abbott, Abbot Park, IL, USA). 
The total analytical imprecision of the cystatin C method was 1.1% at 1.25 mg/L 
and 1.4% at 5.45 mg/L. The equation used for calculating glomerular filtration 
rate (GFR) in mL/min/1.73 m2 from the cystatin C results in mg/mL was y = 
79.901x-1.4389[15]. 
 
Paper II: Apolipoprotein (Apo)A1 and ApoB were measured on an Architect 
Ci8200 analyser (Abbott Laboratories, Abbott Park, IL, USA). 
Paper III: High sensitivity cardiac Troponin I (reagent 3P23) and uric acid 
(reagent 3P39-21) were measured with an Architect Ci16200® analyser (Abbott 
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Laboratories, Abbot Park, IL, USA). The limit of detection of the Troponin I 
assay was 2 ng/L and the total coefficient of variation (CV) was 5.5% at 22 ng/L 
and 4.4% at 200 ng/L. The uric acid method had a total CV of 2.1% at 280 
µmol/L and 0.7% at 580 µmol/L.  
NT-proBNP was measured by a Roche Cobas 8000, using the e602 module 
(Roche Diagnostics, Mannheim, Germany) according to the specifications of the 
manufacturer. The instrument had a total CV of 0.9% at 107 ng/L and 1.3% at 
2060 ng/L. 
 
Autoantibodies:  
Paper I-IV: Antinuclear antibodies (ANA) were analysed by immu- 
nofluorescence (IFL) on sections of rat liver and HEp-2 cells (Immunoconcepts, 
Sacramento, CA, USA).  
Paper I, II and IV: Anticentromere antibodies (ACA), anti-topoisomerase 3 
(ATA), and anti-Sjögren’s syndrome antigen A (anti-SSA) Ro-52 were analysed 
by the multiplex immunoassay BioPlex 2200 ANA screen system (Bio-Rad, 
Hercules, CA, USA).  
Paper III: A line immunoassay (Euroline, Euroimmun Lübeck, Germany) was 
used to detect IgG-antibodies to Scl-70, CENP A, CENPB, RP11, RP155,  
 
Statistics (I-IV) 
Caracteristics of the study populations are described using descriptive statistics: 
for continuous variables, mean +/- standard deviation (SD) are used when 
normally distributed, otherwise median and interquartile range are presented. 
Categorical variables are presented as percentages. Skewed continuous variables 
were log transformed to obtain a normal distribution, if possible. Groups are 
compared using ANOVA or Mann-Whitney U test for continuous variables and 
X2 or Fischers exact test for categorical variables.  
Odds ratio (OR) and 95% confidence intervals (CI) are calculated from 2 × 2 
contingency tables or from nominal logistic regression models. For continuous 
variables, we used standard least squares linear regression to calculate 
standardized regression coefficients (b) and P values. In paper I variables are 
sorted into functional groups (traditional risk factors etc.). After age adjustment, 
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the variables within each group, which were representative and most 
significantly, as determined by lowest P value, associated with the outcome were 
entered into a multivariable-adjusted model. Due to limited number of 
observations , we restricted the number of variables. Calculations were 
performed using JMP software SAS Institute, Cary, NC, USA). A P value < 0.05 
was con- sidered statistically significant. 
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6 RESULTS: 
 
Paper 1:  
We examined the presence of subclinical atherosclerosis in 111 SSc patients and 
105 population based controls, individually matched to the patients for age and 
gender.  The IMT, frequency of plaque and the ABI were compared. We also 
examined the presence of ischemic arterial events (IAE) i.e. ischemic heart 
disease (IHD), ischemic peripheral vascular disease (IPVD) and ischemic 
cerebrovascular disease (ICVD). 
Patients with SSc had a history of more IAE than controls, especially IHD and 
IPVD. Despite this we found no difference between patients and controls 
regarding any of the surrogate markers for atherosclerosis on a group level. SSc 
patient had generally higher levels of biomarkers for inflammation and 
endothelial activation and also higher triglycerides than controls. The patients 
had a lower BMI and lower diastolic blood pressure than controls.  
We found that the ACA+ SSc subgroup had a history of more IAE, IPVD and 
they also had more plaques than controls. Subgroup analyses revealed that the 
ACA+ patients had more plaques and more IAE also compared to other SSc 
patients (after adjustment for age, gender and disease duration). 
 
Figure 4: Ischemic arterial events in ACA+, ACA- and controls, adjusted for 
age, gender and disease duration 
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ACA+ and ACA – patients did not differ regarding inflammatory or endothelial 
biomarkers or traditional risk factors 
Patients with SSc are at enhanced risk for IHD and IPVD especially the ACA+ 
SSc subgroup, which was particularly affected with both ischemic IAE and 
premature atherosclerosis. This group should be followed closely and modifiable 
cardiovascular risk factors should be treated at an early stage. 
 
 
Paper II 
Involvement of the heart is, together with lung manifestations, a major cause of 
premature mortality among SSc patients. Early detection of cardiovascular 
involvement is therefor important. The ECG is an inexpensive, non-invasive and 
commonly available method used to screen for cardiac conduction abnormalities 
and arrhythmias but it is sometimes overlooked in favour to more advanced 
instruments. We performed standard 12-lead ECGs on 110 SSc patients in 
Stockholm County and on 105 gender and age matched population-based 
controls. A subgroup underwent 24-h Holter ECGs. Associations with functional 
outcomes of echocardiography, disease subsets, autoantibodies, and 
cardiovascular risk factors were investigated. 
We found resting ECG-abnormalities in 31 patients and 50 % of these were due 
to conduction abnormalities.  The most common conduction defect was left 
bundle branch block (LBBB). 18 controls had ECG-abnormalities but only 5 had 
conduction defects. Instead non-sinus rhythm was the most common abnormality 
in controls. Septal infarction pattern was only found in four patients but as 
previously described, exclusively in the patient group. All patients with a normal 
ECG had a LVEF >50. ECG abnormalities and/or conduction defects were not 
associated with autoantibodies, inflammation, disease subtype, organ 
involvement or disease duration. Patients had low Apo A1 levels and these were 
associated with both conduction abnormalities and prolonged QTc-time. 
Patients also had more Holter ECG abnormalities than controls and the most 
common abnormality in all participants were ventricular extrasystoles. The 
patients also had a higher mean heart rate than controls. In 50% of the patients 
with holter ECG pathology, the resting ECG was normal. 
It seems as conduction abnormalities and ventricular extra-systoles still are more 
frequent in patients than controls and are not associated with any disease 
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characteristics. Septal infarction pattern was exclusively found in the patients but 
was rare and not associated with any particular clinical characteristics. A 
standard 12-lead ECG is good at detecting conduction defects and a normal ECG 
ruled out severe LV dysfunction but to find potentially severe arrhythmias, 
Holter registrations should be performed. 
 
Paper III 
Cardiac dysfunction in SSc can involve a variety of structures of the heart. 
Yearly screening for PAH is recommended in SSc by international cardiology 
organisations. We performed an echocardiography in 110 patients and 105 
controls, and we investigated how our findings related to cardiac biomarkers.  
44 SSc patients and 23 control subjects had an abnormal echocardiogram 
(P=0.002). As a group SSc patients had lower (but normal) left ventricular 
ejection fraction (LVEF, P=0.02), more regional hypokinesia (P=0.02) and 
more valve regurgitations (p=0.01) than controls. 13 patients and 4 controls 
had previous IHD. SSc patients had low right ventricular (RV) function, 
mostly in combination with LV abnormalities/dysfunction. Fifteen patients 
versus none of the controls had an elevated ePAP. NTproBNP and hs-cTnI 
were higher in SSc patients, and both biomarkers were associated with 
presence of echocardiographic abnormalities. 
 
Table 5. Biomarkers of cardiac stress and its relation to echocardiographic 
abnormalities: 
*: p<0.05, **: p<0.01, ***p<0.001, ****p<0.0001 
 
Biomarkers Abnormal 
echocardiography 
N; 44 
Odd Ratio (CI) 
Estimated PAP 
>34 mmHg 
N: 15 
Odd Ratio (CI) 
Valvular 
insufficiency 
N: 9 
Odd Ratio (CI) 
LVEF<50% and/or 
LV hypokinesia 
N: 12 
Odd Ratio (CI) 
NT-proBNP (ng/L) 2.5 (1.5-4.6)*** 1.9 (1.2-3.2)** 2.4 (1.4-5.0)** 3.2 (1.8-7.1)**** 
hs-cTnI (ng/L) 2.8 (1.3-6.4)** 3.2 (1.4-8.0)** 3.2 (1.1-10.6)* 3.8 (1.7-10.1)** 
Uric acid (µmol/L) 1.01 (1.00-1.01)* 1.00 (0.99-1.00) 1.00 (0.99-1.01) 1.0 (0.99-1.00) 
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SSc patients have a higher prevalence of abnormal echocardiograms than 
controls. Low RV-function and signs of pulmonary hypertension were uniquely 
found in the SSc group. More SSc patients than controls had valvular 
insufficiencies. Both NTproBNP and hs-cTnI were associated with 
echocardiographic abnormalities. Our results suggest that, hs-cTnI, in addition 
to NTproBNP, is a useful new biomarker for cardiac disease in SSc. 
 
Paper IV 
Emerging evidence demonstrate that patients with systemic sclerosis (SSc) suffer 
from both micro- and macrovascular disease. Structural changes in nailfold 
capillaries, is one type of microvascular involvement, which has been associated 
with clinical microvascular symptoms such as digital ulcers and PAH. In this 
study we investigated the association between nailfold capillary changes and 
macrovascular IAE by examining 163 consecutive patients, fulfilling the new 
2013 EULAR/ACR classification criteria for SSc with widefield nailfold 
capillaroscopy. Disease characteristics, autoantibodies, previous digital ulcers, 
IAE, the duration and severity of Raynaud´s phenomenon (RP) and the 
echocardiographic/Doppler estimated pulmonary arterial pressure (ePAP)were 
tabulated. 
Mean age was 61 ± 13 years and 83% were female. Enlarged capillary loops and 
avascular regions were found in 52% and 54% respectively. Mean nailfold 
capillary density was 13.5 ± 4.5 loops/3mm. 13% had a history of IAE, 17% had 
an ePAP>35 and 39% had a history of digital ulcers. Enlarged capillary loops 
were associated with a shorter disease duration and presence of anticentromere 
antibodies (ACA). Occurrence of avascular regions was associated with longer 
disease- and RP duration, ACA, digital ulcer and limited cutaneous SSc. A low 
capillary density was more common among patients with a higher ePAP, ACA, 
digital ulcers and IAE.  
Patients with IAE had a lower nailfold capillary density, but they did not differ 
from other SSc patients with regard to history of digital ulcers, ePAP>35 mmHg, 
enlarged capillary loops or avascular regions. Our results also confirm that a low 
capillary nailfold density is associated with a higher ePAP and with digital 
ulcers.  
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7 DISCUSSION: 
Our studies have highlighted the importance of evaluating both the micro- and 
macrovascular disease in SSc. I would in particular like to focus the concluding 
discussion on the following observations and subjects.   
Subgrouping of the patients: 
We found that patients with ACA had more vasculopathy than patients with 
other autoantibodies. The classical LeRoy subgrouping of SSc patients is defined 
by the distribution of skin involvement (4). It did not correlate with the 
frequency of vascular disease or atherosclerosis in our study. Since the new 
classification criteria also include patients without any skin involvement, future 
studies will probably use antibody subgrouping. These are easier to apply and 
the antibodies also seem to be more reliable, and more clearly associated with 
clinical manifestations. In a large study based on the EULAR database, antibody 
profile was superior to lcSSc/dcSSc to define and predict future organ 
manifestations (52). The antibodies are also stable over time and don’t switch 
from one specificity to another (47). In some cases though, ATA can disappear 
after treatment, but this is uncommon. 
The skin score on the other hand is variable during the course of the disease and 
even without any treatment, skin score declines after many years of SSc. If the 
patient is not diagnosed during the first years of the disease the skin thickness 
and the distribution of skin involvement may regress so that after some time a 
dcSSc patient can “look like” a lcSSc patient. For example: in our cohort, about 
50% of the patients had a disease duration of more than 10 years and even if 
20% of these patients considered to be dcSSc at disease onset, only 2 % still had 
the skin distribution characteristic of the dcSSc subtype at the time of the 
inclusion into this study.  
Characteristics of patients and controls: 
In our studies we chose to include all patients, with no exclusion criteria, to 
determine if macrovascular events and atherosclerosis were more frequent in SSc 
patients than in controls.  We selected population-based controls with no other 
exclusion criteria than a diagnosis of SSc. By this approach we aimed to study 
true differences between patients and controls and also to find differences with 
regard to traditional cardiovascular risk factors. 
When comparing our results with others we note a difference in both the 
selection of patients and controls. Many studies use other patients from other 
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studies (se table 4) or health staff as comparators. Even if the aim is to match for 
age, in many of the previous studies there is often a difference in 2-5 years 
between patients and controls. The frequency of plaques and the IMT rise 
quickly in the age spans where SSc is common, especially after 60 years of age. 
In our study we were able to match our patients with controls very tightly, but 
despite pacemakers and echocardiographic abnormalities were more common 
among controls than expected.  
When asking persons in the general population to participate as controls in a 
study like this it is possible that those, who feel a need for medical check-up. 
Possibly because of appositive CVD heredity or a previous known 
cardiovascular disease, are more likely to accept participation. Our study 
nevertheless demonstrated that SSc patients had more CVD than controls, even if 
the population-based controls may not have been as healthy as expected.  
 
Evaluation of cardiac involvement: 
International heart associations recommend yearly echocardiographic screening 
for PH in SSc patients. In clinical practise this can be difficult to pursue, 
especially when the aim today is to find patients with early SSc, who can have 
their disease for many decades before PH manifests. It has been shown in 
previous studies that clinical symptoms of PH are discrete and when present 
difficult to discriminate from symptoms of interstitial lung disease or cardiac 
ischemia (243).  Several multicentre studies conducted the last ten years have 
resulted in attempts to combine clinical findings with various biomarkers or tests 
in order to detect PH before it is clinical overt (244-246). 
In study II and III we described an enhanced frequency of both rhythm disorders 
and clinically significant echocardiographic abnormalities among SSc patients. 
Conduction disorders were common and in some cases so severe that they had 
caused implantation of a pacemaker. Frequent ventricular extasystoles were also 
detected. In addition to higher ePAP the echocardiographic investigation also 
demonstrate valvular insufficiencies, hypokinesia and low LVEF among SSc 
patients.   
Remembering that cardiac disease together with pulmonary fibrosis and PAH 
constitute the major causes of death in SSc it is important to routinely check for 
cardiac involvement. A standard ECG seems insufficient to detect cardiac 
dysrhythmias; Holter ECG should be conducted at least once and thereafter 
regularly if aberrations are detected or the patient has symptoms.  
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Our studies highlight the importance of a routine check-up with cardiac function 
test, such as echocardiography, not only for detection of suspected PH, but also 
for signs of systolic or diastolic dysfunction and valvular defects.  
  
Biomarkers of cardiac damage:  
NT-proBNP now belongs to the arsenal of “clinical routine” biomarkers. It is 
commonly used to diagnose and monitor heart function, especially in heart 
failure, but it is also used in the evaluation of disease severity of PH/PAH. Even 
if it is a good marker for cardiac failure, it can´t detect the pathophysiologic 
background of the heart disease. In our study III we found that cTnI was higher 
in patients with SSc than controls and that it was associated with 
echocardiographic abnormalities. The high levels of cTnI were not associated 
with any specific echocardiographic abberation; it seemed to be higher in both 
patients with elevated ePAP, valve regurgitations and reduced 
LVEF/hypokinesia. In some patients they were elevated in the absence 
echocardiographic abnormalities. There could be several explanation for the 
elevated cTnI  seen in SSc patients:  
¥ Underlying heart disease in SSc patients such as PAH or cardiac failure. 
¥ Previous myocardial damage such as myocardial inflammation or 
ischemic heart disease. 
¥ Cytotoxic drugs such as cyclophosphamide are known to be toxic for the 
heart. In oncology, cTn are used to monitor cardiotoxic effects. 
Intrestingly in the study by Pieroni et al, 7 SSc patients with elevated 
cTnT had evidence of myocarditis on biopsy and the majority had an 
reduction of cTnI after treatment with cyclophosphamide 
¥ Other diseases infiltrating the heart, e.g  amyloidosis and sarcoidosis 
have elevated troponins.  
 
Our results imply that cTn is a new potential biomarker for the surveillance of 
heart involvement in SSc. It is however important to study cTn further in order 
to validate their role as possible biomarkers for SSc related cardiac disease. It is 
in particular essential to determine if they can discriminate between different 
types of cardiac involvement, if they have any prognostic implications and if 
treatment can influence the levels.   
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Microvascular versus macrovascular disease: 
Myocardial infarction, angina pectoris, stroke and peripheral arterial vascular 
diseases are described as typical macrovascular diseases. Our study highlights 
the close association between macro- and microvascular diseases.  
We found a higher frequency of both IHD and IPVD in SSc patients than 
controls and in SSc patients; especially IPVD was associated with a reduced 
capillary density. In ACA positive patients we also noticed that atherosclerosis is 
accelerated. These results are really intriguing. It has been reported in two 
studies that patients who are positive for ACA are more prone to have severe 
digital ulcers, which may lead to amputation.(247). Despite this fact most of the 
recent studies today favours that an increased risk of digital ulcers is present in 
SSc patients with ATA.  
Our results imply that the seldom-recognized macrovascular disease in the ACA 
positive group may cause or be an important contributor to digital ulcers.  
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8 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES: 
 
This thesis has focused on macro- and microvascular disease in systemic 
sclerosis. 
¥ Manifest ischemic arterial disease, engaging the heart and the peripheral 
vasculature is more common in SSc patients as compared to the general 
population. 
¥ The enhanced occurrence of ischemic vascular disease in SSc is essentially 
confined to the ACA + SSc subgroup, and this subgroup is also affected 
with accelerated atherosclerosis. 
¥ Conduction defects and arrhythmias are still as prevalent in SSc patients as 
they were 25 years ago. 
¥ Patients with SSc have elevated markers of cardiac damage, and this is 
associated with echocardiographic findings. 
¥ Patients with manifest ischemic arterial disease, especially peripher arterial 
disease, have an impaired microcirculation. 
 
  
Future perspectives 
 
All studies in this thesis are cross-sectional. This design has the limitation that 
we can only study survivors of CVD in SSc. We can thus not give truly reliable 
answers to what are the underlying causes for the high frequency of ischemic 
arterial events in SSc. For this purpose it is important to follow the patients 
longitudinally to see who will develop future macrovascular events. We are 
presently following our cohort prospectively for five years with collection of 
clinical data and blood samples. We hope that these ongoing studies will shed 
more light upon the underlying factors for IAE in patients with SSc. We are also 
going to compare SSc patients with matched SLE patients, a patient group 
known to have an exceptionally high risk for CVD. The objective of this study is 
to find differences and similarities between these two autoimmune diseases with 
regard to CVD risk factors and outcomes. 
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We also plan to study the impact of microparticles, platelets, type 1interferon, 
HLA-genotypes, phospholipid antibodies on both micro- and macrovascular 
disease in SSc:  
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